CD47: role in the immune system and application to cancer therapy

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy

(2019) Meike E. W. Logtenberg et al.   NATURE MEDICINE

Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma

(2018) Xuyao Zhang et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index

(2018) Yun Yang et al.   BIOTECHNOLOGY LETTERS

Abstract 2709: TTI-622 (SIRPα-IgG4 Fc), a CD47-blocking innate immune checkpoint inhibitor, suppresses tumor growth and demonstrates enhanced efficacy in combination with antitumor antibodies in both hematologic and solid tumor models

(2018) Gloria H. Y. Lin et al.   CANCER RESEARCH

Efferocytosis: molecular mechanisms & pathophysiological perspective

(2018) Seyed Mohammad Gheibi hayat et al.   IMMUNOLOGY AND CELL BIOLOGY

ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile

(2018) Steven E. Kauder et al.   PLoS One

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

(2016) Penka S. Petrova et al.   CLINICAL CANCER RESEARCH

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

(2016) Jonathan T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis

(2016) Lu Gao et al.   Oncotarget

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

(2015) Emily C Piccione et al.   mAbs

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma

(2014) Terence Kin-Wah Lee et al.   HEPATOLOGY

CD47 Expression on T Cell Is a Self-Control Negative Regulator of Type 1 Immune Response

(2014) S. Bouguermouh et al.   JOURNAL OF IMMUNOLOGY

The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target

(2013) A. Neil Barclay et al.   Annual Review of Immunology

A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity

(2013) Valerie R. Wiersma et al.   BRITISH JOURNAL OF HAEMATOLOGY

Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration

(2013) Yuan Zhang et al.   EUROPEAN JOURNAL OF CANCER

Intravenous Delivery of siRNA Targeting CD47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis

(2013) Yuhua Wang et al.   MOLECULAR THERAPY

Achieving efficient RNAi therapy: progress and challenges

(2013) Kun Gao et al.   Acta Pharmaceutica Sinica B

The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications

(2012) Mark P Chao et al.   CURRENT OPINION IN IMMUNOLOGY

CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma

(2012) SHIGEMASA SUZUKI et al.   ONCOLOGY REPORTS

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy

(2011) M. P. Chao et al.   BLOOD

A new disulfide-linked dimer of a single-chain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells via the hypoxia inducible factor-1α pathway

(2011) Morihiko Sagawa et al.   CANCER SCIENCE

Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia

(2010) Mark P. Chao et al.   CANCER RESEARCH

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4+ T Cells

(2010) J. J. O'Shea et al.   SCIENCE

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

CD47 Regulates Collagen I-Induced Cyclooxygenase-2 Expression and Intestinal Epithelial Cell Migration

(2009) Oliver Jay Broom et al.   PLoS One

Functions and molecular mechanisms of the CD47–SIRPα signalling pathway

(2009) Takashi Matozaki et al.   TRENDS IN CELL BIOLOGY

Differential Interactions of Thrombospondin-1, -2, and -4 with CD47 and Effects on cGMP Signaling and Ischemic Injury Responses

(2008) Jeff S. Isenberg et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells

(2008) Richard K. Tsai et al.   JOURNAL OF CELL BIOLOGY

Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD47

(2008) Deborah Hatherley et al.   MOLECULAR CELL

Association of CD47 with Natural Killer Cell-Mediated Cytotoxicity of Head-and-Neck Squamous Cell Carcinoma Lines

(2008) Min Jung Kim et al.   TUMOR BIOLOGY

CD47 associates with alpha 5 integrin and regulates responses of human articular chondrocytes to mechanical stimulation in an in vitro model

(2008) Mahmoud Orazizadeh et al.   ARTHRITIS RESEARCH & THERAPY